Review articles and clinical analyses in Stroke
A device that promises to restore swallowing in 30 minutes over 3 days sounds extraordinary — but the largest randomized trial was negative, the positive trial was stopped early with…
After decades of stagnation in non-cardioembolic stroke prevention, we finally have a new antithrombotic class that works. OCEANIC-STROKE showed that asundexian reduced recurrent stroke by 26% with no increase in…
Meta-analyses show a 16% stroke reduction. The 2024 AHA/ASA guidelines give GLP-1 RAs a Class I recommendation for stroke prevention. But in most individual trials, the stroke component wasn't significant.…
For two decades, we've watched LDL targets in secondary stroke prevention steadily decline. What started as a cardiologist's target of <100 mg/dL has moved to <70, and now <55 for…
Two decades of research have progressively extended the thrombolysis window from 3 to 4.5 to potentially 24 hours. But the path hasn't been linear—early trials targeting large vessel occlusions showed…
